|
Abbreviated name: BTLA
Synonyms: B- and T-lymphocyte attenuator | B- and T-lymphocyte-associated protein | CD272
Compound class:
Endogenous peptide in human, mouse or rat
Comment: BTLA is a negative immunomodulator. Interaction of BTLA with TNFRSF14 (HVEM) constitutes an immune checkpoint which inhibits T cell-mediated immune responses. Dysregulated BTLA expression contributes to immunosuppression and progression of some cancers [1-4] by enabling tumour immune evasion. Immunotherapeutics that target the BTLA-HVEM checkpoint offer potential as anti-tumour agents [5-6].
Species: Human
|
| Natural/Endogenous Targets | ||
|
||
| Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
